Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when VTGN files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsVistagen receives FDA clearance to begin Phase 2 U.S. trials for menopause treatment
Filed April 28, 2026 · Period ending April 22, 2026 · ~1 min read
Key Changes
-
high
FDA issued Study May Proceed letter for refisolone nasal spray, clearing Phase 2 trials in the U.S. for moderate to severe hot flashes in menopausal women. This non-hormonal treatment builds on earlier exploratory studies in Mexico.
Item 8.01 verify on EDGAR → -
medium
Refisolone is a non-systemic, non-hormonal product candidate, differentiating it from traditional hormone replacement therapies for menopause symptoms.
Press Release verify on EDGAR →
Summary
Vistagen Therapeutics announced FDA clearance to proceed with Phase 2 clinical trials of refisolone nasal spray in the United States. The Study May Proceed letter allows the company to advance testing of this non-hormonal treatment for moderate to severe hot flashes in menopausal women, a large potential market where many patients seek alternatives to hormone therapy.
For retail investors, this regulatory milestone moves refisolone closer to potential commercialization and validates the company's development pathway. The non-hormonal, non-systemic profile may appeal to women who cannot or prefer not to use hormone replacement therapy. However, Phase 2 trials are still early-stage, and significant clinical and regulatory hurdles remain before any potential product approval.
Watch for enrollment timelines and trial design details in upcoming investor communications. Success in these U.S. trials would be critical for advancing refisolone toward pivotal Phase 3 studies.
Section-by-Section Diff
Event · Item 9.01 — Financial Statements and Exhibits
Vistagen filed an 8-K attaching a press release dated April 22, 2026; no material business event disclosed in the filing body.
Added in current filing · verify on EDGAR →
Press Release issued by Vistagen Therapeutics, Inc., dated April 22, 2026
The 8-K discloses that a press release dated April 22, 2026 has been attached as Exhibit 99.1. The filing body does not describe the content of the press release, so the nature of the disclosed event cannot be determined from this 8-K text alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 10, 2026 · How we verify